INTRODUCTION
Every malignant tumor is probably derived from a single progenitor that had acquired growth and survival advantages through genetic and epigenetic changes, allowing clonal expansion (Nowell, 1976) . Tumor progenitors are not necessarily identical to cancer stem cells (CSCs), which maintain and renew fully established malignancies (Nguyen et al., 2012) . However, clonal evolution and selective pressure may cause some descendants of the initial progenitor to cross the bridge of no return and form a premalignant lesion. Cancer genome sequencing indicates that most cancers require at least five genetic changes to evolve (Wood et al., 2007) . How these changes affect the properties of tumor progenitors and control their evolution into a CSC is not entirely clear, as it has been difficult to isolate and propagate cancer progenitors prior to detection of tumor masses. Given these difficulties, it is also not clear whether cancer progenitors are the precursors for the more malignant CSC isolated from fully established cancers. An answer to these critical questions depends on identification and isolation of cancer progenitors, which may also enable definition of molecular markers and signaling pathways suitable for early detection and treatment. This is especially important in cancers of the liver and pancreas, which evolve over the course of many years but, once detected, are extremely difficult to treat (El-Serag, 2011; Hruban et al., 2007) .
Hepatocellular carcinoma (HCC), the most common liver cancer, is the end product of chronic liver diseases, requiring several decades to evolve (El-Serag, 2011) . Currently, HCC is the third most deadly and fifth most common cancer worldwide, and in the United States its incidence has doubled in the past two decades. Furthermore, 8% of the world's population are chronically infected with hepatitis B or C viruses (HBV and HCV) and are at a high risk of new HCC development (El-Serag, 2011) . Up to 5% of HCV patients will develop HCC in their lifetime, and the yearly HCC incidence in patients with cirrhosis is 3%-5%. These tumors may arise from premalignant lesions, ranging from dysplastic foci to dysplastic hepatocyte nodules that are often seen in damaged and cirrhotic livers and are more proliferative than the surrounding parenchyma (Hytiroglou et al., 2007) . However, the tumorigenic potential of these lesions was never examined, and it is unknown whether they contain any genetic alterations. Given that there is no effective treatment for HCC and, upon diagnosis, most patients with advanced disease have a remaining lifespan of 4-6 months, it is important to detect HCC early, while it is still amenable to surgical resection or chemotherapy. Premalignant lesions, called foci of altered hepatocytes (FAH), were also described in chemically induced HCC models (Pitot, 1990) , but it was questioned whether these lesions harbor tumor progenitors or result from compensatory proliferation (Sell and Leffert, 2008) . The aim of this study was to determine whether HCC progenitor cells (HcPCs) exist and if so, to isolate these cells and identify some of the signaling networks that are involved in their maintenance and progression.
We now describe HcPC isolation from mice treated with the procarcinogen diethyl nitrosamine (DEN), which induces poorly differentiated HCC nodules within 8 to 9 months (Verna et al., 1996) . Although these tumors do not evolve in the context of cirrhosis, the use of a chemical carcinogen is justified because the finding of up to 121 mutations per HCC genome suggests that carcinogens may be responsible for human HCC induction (Guichard et al., 2012) . Furthermore, 20%-30% of HCC, especially in HBV-infected individuals, evolve in noncirrhotic livers (El-Serag, 2011) . Nonetheless, we also isolated HcPCs from Tak1
Dhep mice, which develop spontaneous HCC as a result of progressive liver damage, inflammation, and fibrosis caused by ablation of TAK1 (Inokuchi et al., 2010) . Although the etiology of each model is distinct, both contain HcPCs that express marker genes and signaling pathways previously identified in human HCC stem cells (Marquardt and Thorgeirsson, 2010) long before visible tumors are detected. Furthermore, DENinduced premalignant lesions and HcPCs exhibit autocrine IL-6 production that is critical for tumorigenic progression. Circulating IL-6 is a risk indicator in several human pathologies and is strongly correlated with adverse prognosis in HCC and cholangiocarcinoma (Porta et al., 2008; Soresi et al., 2006) . IL-6 produced by in-vitro-induced CSCs was suggested to be important for their maintenance (Iliopoulos et al., 2009 ). Furthermore, autocrine IL-6 was detected in several cancers, but its origin is poorly understood (Grivennikov and Karin, 2008) . In particular, little is known about the source of IL-6 in HCC. In early stages of hepatocarcinogenesis, IL-6 is produced by Kupffer cells or macrophages (Maeda et al., 2005; Naugler et al., 2007) . However, paracrine IL-6 production is transient and does not explain its expression by HCC cells.
RESULTS

DEN-Induced Collagenase-Resistant Aggregates of HCC Progenitors
A single intraperitoneal (i.p.) injection of DEN into 15-day-old BL/6 mice induces HCC nodules first detected 8 to 9 months later. However, hepatocytes prepared from macroscopically normal livers 3 months after DEN administration already contain cells that progress to HCC when transplanted into the permissive liver environment of MUP-uPA mice , which express urokinase plasminogen activator (uPA) from a mouse liver-specific major urinary protein (MUP) promoter and undergo chronic liver damage and compensatory proliferation (Rhim et al., 1994) . Collagenase digestion of DEN-treated livers generated a mixture of monodisperse hepatocytes and aggregates of tightly packed small hepatocytic cells ( Figure 1A ). Aggregated cells were also present-but in lower abundance-in digests of control livers (Figure S1A available online). HCC markers such as a fetoprotein (AFP), glypican 3 (Gpc3), and Ly6D, whose expression in mouse liver cancer was reported (Meyer et al., 2003) , were upregulated in aggregates from DEN-treated livers, but not in nonaggregated hepatocytes or aggregates from control livers ( Figure S1A ). Thus, control liver aggregates may result from incomplete collagenase digestion, whereas aggregates from DEN-treated livers may contain HcPC. DEN-induced aggregates became larger and more abundant 5 months after carcinogen exposure, when they consisted of 10-50 cells that were smaller than nonaggregated hepatocytes. Using 70 mm and 40 mm sieves, we separated aggregated from nonaggregated hepatocytes ( Figure 1A ) and tested their tumorigenic potential by transplantation into MUP-uPA mice ( Figure 1B ). To facilitate transplantation, the aggregates were mechanically dispersed and suspended in Dulbecco's modified Eagle's medium (DMEM). Five months after intrasplenic (i.s.) injection of 10 4 viable cells, mice receiving cells from aggregates developed about 18 liver tumors per mouse, whereas mice receiving nonaggregated hepatocytes developed less than 1 tumor each (Figure 1B) . The tumors exhibited typical trabecular HCC morphology and contained cells that abundantly express AFP ( Figure S1B ). To confirm that the HCCs were derived from transplanted cells, we measured their relative MUP-uPA DNA copy number and found that they contained much less MUP-uPA transgene DNA than the surrounding parenchyma ( Figure S1C ). Transplantation of aggregated cells from livers of DEN-treated actin-GFP transgenic mice resulted in GFP-positive HCCs ( Figure S1D ). Both experiments strongly suggest that the HCCs were derived from the transplanted cells. No tumors were ever observed after transplantation of control hepatocytes (nonaggregated or aggregated). Only liver tumors were formed by the transplanted cells. Other organs, including the spleen into which the cells were injected, remained tumor free ( Figure 1B) , suggesting that HcPCs progress to cancer only in the proper microenvironment. Indeed, no tumors appeared after HcPC transplantation into normal BL/6 mice. But, if BL/6 mice were first treated with retrorsine (a chemical that permanently inhibits hepatocyte proliferation [Laconi et al., 1998 ]), intrasplenically transplanted with HcPC-containing aggregates, and challenged with CCl 4 to induce liver injury and compensatory proliferation (Guo et al., 2002) , HCCs readily appeared ( Figure 1C ). CCl 4 omission prevented tumor development. Notably, MUP-uPA or CCl 4 -treated livers are fragile, rendering direct intrahepatic transplantation difficult. The transplanted HcPC-containing aggregates formed more numerous and larger HCC nodules in male recipients than in females (Figure 1C) , as observed in MUP-uPA mice transplanted with unfractionated DEN-exposed hepatocytes . Thus, CCl 4 -induced liver damage, especially within a male liver, generates a microenvironment that drives HcPC proliferation and malignant progression. To examine this point, we transplanted GFP-labeled HcPC-containing aggregates into retrorsinetreated BL/6 mice and examined their ability to proliferate with or without subsequent CCl 4 treatment. Indeed, the GFP + cells formed clusters that grew in size only in CCl 4 -treated host livers ( Figure S1E ). Omission of CC1 4 prevented their expansion. Unlike HCC-derived cancer cells (dih10 cells), which form subcutaneous (s.c.) tumors with HCC morphology Park et al., 2010) , the HcPC-containing aggregates did not generate s.c. tumors in BL/6 mice ( Figure S1F ). Despite their homogeneous appearance, the HcPC-containing aggregates contained both CD44 + and CD44 À cells (Figure 1D) . Because CD44 is expressed by HCC stem cells (Yang et al., 2008; Zhu et al., 2010) , we dispersed the aggregates and separated CD44 + from CD44 À cells and transplanted both into MUP-uPA mice. Whereas as few as 10 3 CD44 + cells gave rise to HCCs in 100% of recipients, no tumors were detected after transplantation of CD44 À cells ( Figure 1E ). Remarkably, 50% of recipients developed at least one HCC after receiving as few as 10 2 CD44 + cells. Mature CD44 À hepatocytes were found to engraft as well as or better than CD44 + small hepatocytic cells (Haridass et al., 2009; Ichinohe et al., 2012) . Hence, livers of DEN-treated mice contain CD44 + HcPC that can be successfully isolated and purified and give rise to HCCs after transplantation into appropriate hosts. Unlike fully transformed HCC cells, HcPCs only give rise to tumors within the liver.
HcPC-Containing Aggregates in Tak1
Dhep Mice
We applied the same HcPC isolation protocol to Tak1 Dhep mice, which develop HCC of different etiology from DEN-induced HCC. Importantly, Tak1 Dhep mice develop HCC as a consequence of chronic liver injury and fibrosis without carcinogen or toxicant exposure (Inokuchi et al., 2010) . Indeed, whole-tumor exome sequencing revealed that DEN-induced HCC contained about 24 mutations per 10 6 bases (Mb) sequenced, with B-Raf V637E being the most recurrent, whereas 1.4 mutations per Mb were detected in Tak1 Dhep HCC's exome (Table S1 ). By
contrast, Tak1
Dhep HCC exhibited gene copy number changes.
Collagenase digests of 1-month-old Tak1
Dhep livers contained much more hepatocytic aggregates than Tak1 f/f liver digests ( Figure 2A ). Notably, HCC developed in 75% of MUP-uPA mice that received dispersed Tak1
Dhep aggregates, but no tumors appeared in mice receiving nonaggregated Tak1 Dhep or total Tak1 f/f hepatocytes ( Figure 2B ). Because Tak1 Dhep mice are subject to chronic liver damage and consequent compensatory proliferation, we wanted to ascertain that the HcPCs are not simply proliferating hepatocytes or expanding bipotential hepatobiliary progenitors using CCl 4 to induce liver injury and compensatory proliferation in WT mice. Although this treatment caused acute liver fibrosis, it did not augment formation of collagenase-resistant aggregates ( Figure 2C ). Similarly, few aggregates were detected in collagenase digests of livers after partial hepatectomy ( Figure 2D ). However, bile duct ligation (BDL) or feeding with 3,5-dicarbethoxy-1,4-dihydrocollidine (DDC), treatments that cause cholestatic liver injuries and oval cell expansion , did increase the number of small hepatocytic cell aggregates ( Figure S2A ). Nonetheless, no tumors were observed 5 months after injection of such aggregates into MUP-uPA mice ( Figure S2B ). Thus, not all hepatocytic aggregates contain HcPCs, and HcPCs only appear under tumorigenic conditions. Figure S2 and Table S1 . hepatocyte samples did not cluster with each other but rather with nonaggregated hepatocytes derived from the same mouse ( Figure S3A ). Interestingly, the aggregated cell transcriptome appeared closer to that of normal hepatocytes than to the HCC profile. This similarity may be due to the presence of $70% nontumorigenic (or CD44 À ) hepatocytes within the purified aggregates ( Figure 1D) . Comparison of the HCC and normal hepatocyte transcriptomes revealed 1,912 differentially expressed genes (false discovery rate [FDR] < 0.01; Figure 3A , left, cyan dots). A similar comparison revealed 1,020 genes that are differentially expressed between aggregated and nonaggregated hepatocytes (FDR < 0.01; Figure 3A , right, red dots). The range of differential expression is wider for the HCC and normal hepatocyte pair than the aggregate versus nonaggregate pair, reflecting presence of normal, nontransformed hepatocytes within the aggregates, resulting in signal dilution. Interestingly, 57% (583/ 1,020) of genes differentially expressed in aggregated relative to nonaggregated hepatocytes are also differentially expressed in HCC relative to normal hepatocytes ( Figure 3B , top), a value that is highly significant (p < 7.13 3 10
À243
). More specifically, 85% (494/583) of these genes are overexpressed in both HCC and HcPC-containing aggregates ( Figure 3B, bottom table) . Thus, hepatocyte aggregates isolated 5 months after DEN injection contain cells that are related in their gene expression profile to HCC cells isolated from fully developed tumor nodules.
To gain insight into the functional differences between the transcriptomes of the four populations, we examined which biological processes or cellular compartments were significantly overrepresented in the induced or repressed genes in both pairwise comparisons (Gene Ontology Analysis). As expected, processes and compartments that were enriched in aggregated hepatocytes relative to nonaggregated hepatocytes were almost identical to those that were enriched in HCC relative to normal hepatocytes ( Figure 3C ). Upregulated genes were related to immune response, angiogenesis, development, and wound healing, and many encoded plasma membrane or secreted proteins. By contrast, downregulated genes were highly enriched for metabolic processes, and many of them encoded mitochondrial proteins or had functions associated with differentiated hepatocytes ( Figure 3C ). Several human HCC markers, including AFP, Gpc3 and H19, were upregulated in aggregated hepatocytes ( Figures 3D and 3E ). Aggregated hepatocytes also expressed more Tetraspanin 8 (Tspan8), a cell-surface glycoprotein that complexes with integrins and is overexpressed in human carcinomas (Zö ller, 2009). Another cell-surface molecule highly expressed in aggregated cells is Ly6D (Figures 3D and 3E) . Immunofluorescence (IF) analysis revealed that Ly6D was undetectable in normal liver but was elevated in FAH and ubiquitously expressed in most HCC cells ( Figure S3C) . A fluorescent-labeled Ly6D antibody injected into HCC-bearing mice specifically stained tumor nodules ( Figure S3D ). Other cell-surface molecules that were upregulated in aggregated cells included syndecan 3 (Sdc3), integrin a 9 (Itga9), claudin 5 (Cldn5), and cadherin 5 (Cdh5) ( Figure 3D ). Aggregated hepatocytes also exhibited elevated expression of extracellular matrix proteins (TIF3 and Reln1) and a serine protease inhibitor (Spink3). Elevated expression of such proteins may explain aggregate formation. Aggregated hepatocytes also expressed progenitor cell markers, including the epithelial cell adhesion molecule (EpCAM) (Figure 3E ) and Dlk1 ( Figure 3D ). Elevated expression of cytokines and cytokine receptors was also detected, including tumor necrosis factor superfamily members 12 and 21, colony-stimulating factor 1 receptor, FMS-like tyrosine kinase 1, chemokine (C-X-C motif) ligand 9, the STAT3-activating cytokine osteopontin, IL-6 receptor (IL-6R) signal transducing subunit (gp130), and oncostatin M (OSM) receptor, which also activates STAT3 ( Figure 3D ).
Aggregated hepatocytes expressed albumin, albeit less than nonaggregated hepatocytes ( Figure 4A ). Some aggregated cells were positive for cytokeratin 19 (CK19) and A6, markers for bile duct epithelium and oval cells ( Figure 4A ). Most cells in the DENinduced aggregates were AFP positive, and some of them expressed EpCAM ( Figure 4A ). However, not all markers were expressed by every cell within a given aggregate, suggesting that the aggregates contain liver cells that are related to bipotential hepatobiliary progenitors/oval cells as well as more differentiated progeny and normal hepatocytes. To confirm these observations, we compared the HcPC and HCC ( Figure 3A) to the transcriptome of DDC-induced oval cells (Shin et al., 2011) . This analysis revealed a striking similarity between the HCC, HcPC, and the oval cell transcriptomes ( Figure S3B ). Despite these similarities, some genes that were upregulated in HcPCcontaining aggregates and HCC were not upregulated in oval cells. Such genes may account for the tumorigenic properties of HcPC and HCC.
We examined the aggregates for signaling pathways and transcription factors involved in hepatocarcinogenesis. hepatocarcinogenesis (Eferl et al., 2003; He et al., 2010) . Sox9, a transcription factor that marks hepatobiliary progenitors , was also expressed by many of the aggregated cells, which were also positive for phosphorylated c-Met (Figure 4A) , a receptor tyrosine kinase that is activated by hepatocyte growth factor (HGF) and is essential for liver development (Bladt et al., 1995) and hepatocarcinogenesis (Wang et al., 2001 ). Few of the nonaggregated hepatocytes exhibited activation of these signaling pathways. Aggregates from bromodeoxyuridine (BrdU)-pulsed DEN-treated mice contained BrdU-positive cells ( Figure 4B ), indicating that they were actively proliferating prior to isolation. Hepatocyte aggregates from 1-month-old Tak1 See also Figure S4 .
HcPC-Containing Aggregates
Originate from Premalignant Dysplastic Lesions FAH are dysplastic lesions occurring in rodent livers exposed to hepatic carcinogens (Su et al., 1990) . Similar lesions are present in premalignant human livers (Su et al., 1997 ). Yet, it is still debated whether FAH correspond to premalignant lesions or are a reaction to liver injury that does not lead to cancer (Sell and Leffert, 2008) . In DEN-treated males, FAH were detected as early as 3 months after DEN administration ( Figure 5A ), concomitant with the time at which HcPC-containing aggregates were detected. In females, FAH development was delayed. In both genders, FAH were confined to zone 3 and consisted of tightly packed small hepatocytic cells, some of which were proliferative based on BrdU incorporation ( Figure 5B ). BrdU + cells were first detected in DEN-treated males and were confined to FAH and rarely detected in age-matched control mice. FAH contained cells positive for the same progenitor cell markers and activated signaling pathways present in HcPC-containing aggregates, including AFP, CD44, and EpCAM ( Figure 5C ). FAH also contained cells positive for activated STAT3, c-Jun, and PCNA ( Figure 5C ). Many cells within FAH exhibited strong upregulation of YAP ( Figure 5C ), a transcriptional coactivator that is negatively regulated by the Hippo pathway and a liver cancer oncoprotein (Zheng et al., 2011) . FAH were also enriched in F4/ 80 + macrophages ( Figure 5C ). These results suggest that the HcPC-containing aggregates may be derived from FAH.
HcPCs Exhibit Autocrine IL-6 Expression Necessary for HCC Progression
In situ hybridization (ISH) and immunohistochemistry (IHC) revealed that DEN-induced FAH contained IL-6-expressing cells ( Figures 6A, 6B , and S5), and freshly isolated DEN-induced aggregates contained more IL-6 messenger RNA (mRNA) than nonaggregated hepatocytes ( Figure 6C ). We examined several factors that control IL-6 expression and found that LIN28A and B were significantly upregulated in HcPCs and HCC ( Figures 6D  and 6E ). LIN28-expressing cells were also detected within FAH ( Figure 6F ). As reported (Iliopoulos et al., 2009 ), knockdown of LIN28B in cultured HcPC or HCC cell lines decreased IL-6 expression ( Figure 6G ). LIN28 exerts its effects through downregulation of the microRNA (miRNA) Let-7 (Iliopoulos et al., 2009) . Accordingly, miRNA array analysis of aggregated and nonaggregated hepatocytes from DEN-treated mice indicated that the amount of Let-7, along with other miRNAs that also inhibit IL-6 expression (miR194 and miR872), was lower in aggregated cells than in nonaggregated cells (Table S2) .
To determine whether autocrine IL-6 production is needed for HCC growth, we silenced IL-6 expression with small hairpin RNA (shRNA) in dih10 HCC cells . This resulted in nearly a 75% decrease in IL-6 mRNA ( Figure 7A ) but had little effect on cell growth in the presence of growth factors, including EGF and insulin ( Figure S6A ). IL-6 mRNA silencing, however, diminished the ability of dih10 cells to form s.c. tumors ( Figures  S6B and S6C ) and inhibited their ability to form HCCs and proliferate after transplantation into MUP-uPA mice ( Figures 7B and  S6D) . To investigate the importance of autocrine IL-6 production at an earlier step, we isolated HcPC from DEN-treated WT and Il6 À/À mice. Although IL-6 ablation attenuates HCC induction (Naugler et al., 2007) IL-6 deficiency resulted in a 2.5-fold decrease in tumorigenic potential (Figure 7C ), suggesting that autocrine IL-6 contributes to HcPC to HCC progression.
To confirm this point, we dispersed freshly isolated DEN-induced aggregates and transduced them with bicistronic lentiviruses encoding either scrambled or IL-6-specific shRNAs and a GFP marker. After a few days in culture, the transduced cells were introduced into MUP-uPA mice that were examined for HCC development 6 months later. Silencing of IL-6 reduced HCC generation ( Figure 7D ) and inhibited formation of GFP + colonies within the MUP-uPA liver ( Figure 7E ). We also ablated IL-6 expression in mouse hepatocytes and found that this led to a marked reduction in DEN-induced tumorigenesis ( Figure 7F ). Thus, autocrine IL-6 production by DEN-initiated HcPC is important for HCC development. To investigate whether autocrine IL-6 signaling also occurs in human premalignant lesions, we examined needle biopsies of normal liver tissue and HCV-infected livers with dysplastic lesions. We found that 16% of all (n = 25) dysplastic lesions exhibited coexpression of LIN28 and IL-6 and contained activated STAT3 ( Figure 7G ). These markers were hardly detected in normal liver or nontumor portion of HCV-infected livers.
DISCUSSION
The isolation and characterization of cells that can give rise to HCC only after transplantation into an appropriate host liver undergoing chronic injury demonstrates that cancer arises from progenitor cells that are yet to become fully malignant. Importantly, unlike fully malignant HCC cells, the HcPCs we isolated cannot form s.c. tumors or even liver tumors when introduced into a nondamaged liver. Liver damage induced by uPA expression or CCl 4 treatment provides HcPCs with the proper cytokine and growth factor milieu needed for their proliferation. Although HcPCs produce IL-6, they may also depend on other cytokines such as TNF, which is produced by macrophages that are recruited to the damaged liver. In addition, uPA expression and CCl 4 treatment may enhance HcPC growth and progression through their fibrogenic effect on hepatic stellate cells. Although HCC and other cancers have been suspected to arise from premalignant/dysplastic lesions (Hruban et al., 2007; Hytiroglou et al., 2007) , a direct demonstration that such lesions progress into malignant tumors has been lacking. Based on expression of common markers-EpCAM, CD44, AFP, activated STAT3, and IL-6-that are not expressed in normal hepatocytes, we postulate that HcPCs originate from FAH or dysplastic foci, which are first observed in male mice within 3 months of DEN exposure. Indeed, the cells that are contained within the FAH are smaller than the surrounding parenchyma and are similar in size to isolated HcPCs. Importantly, FAH or premalignant dysplastic foci are not unique to DEN-treated rodents (Bannasch, 1984; Rabes, 1983) , and similar lesions were detected in human cirrhotic livers (Hytiroglou et al., 2007; Seki et al., 2000; Takayama et al., 1990) in which the rate of HCC progression is 3%-5% per year (El-Serag, 2011). We found that human See also Figure S5 and Table S2 .
dysplastic lesions and mouse FAH and HcPC exhibit autocrine IL-6 signaling. HcPC are not unique to DEN-treated mice, and similar cells were isolated from Tak1 Dhep mice in which HCC development resembles cirrhosis-associated human HCC (Inokuchi et al., 2010) .
HcPC Origin and Relationship to Liver and HCC Stem Cells
Transcriptomic analysis indicates that DEN-induced HcPCs are related to both normal hepatobiliary bipotential stem cells/oval cells and HCC cells. Although HcPCs are not fully transformed, they express several markers-CD44, EpCAM, AFP, SOX9, OV6, and CK19-found to be expressed by HCC stem cells and oval cells (Guo et al., 2012; Mikhail and He, 2011; Terris et al., 2010; Yamashita et al., 2008; Zhu et al., 2010) . However, unlike oval cells, which do not express albumin or AFP and do not give rise to liver tumors upon transplantation into MUPuPA mice, HcPCs give rise to HCC after intrasplenic transplantation. Yet, unlike dih10 HCC cells, which express high levels of the HCC stem cell markers AFP, CD44, and EpCAM, HcPCs do not form s.c. tumors.
At this point, it is not clear whether HcPCs arise from oval cells or from dedifferentiated hepatocytes. Given that DEN is metabolically activated by Cyp2E1 that is expressed only in fully differentiated zone 3 hepatocytes (Tsutsumi et al., 1989) and that Cyp2E1 À/À mice are refractory to DEN (Kang et al., 2007) , DEN-induced HcPC are most likely derived from dedifferentiated hepatocytes. Consistent with this hypothesis, DEN-induced FAH and proliferating cells were found in zone 3 and not near bile ducts or the canals of Hering, sites at which oval cells reside (Duncan et al., 2009) . Notably, GO analysis revealed that many of the genes whose expression is downregulated in HcPC-containing aggregates are involved in xenobiotic and organic acid metabolism, characteristics of differentiated hepatocytes. The same types of genes are also downregulated in HCC. However, final identification of the origin of HcPC will be provided by ongoing lineage-tracing experiments.
The Significance of Autocrine IL-6 Expression Elevated IL-6 was detected in at least 40% of human HCCs, where it is expressed by the cancer cells (Soresi et al., 2006) . More recent studies have confirmed upregulation of IL-6 in human HCC and suggested that it plays a central role in a gene expression network that drives tumor development (Ji et al., 2009) . Elevated IL-6 was also found in viral and alcoholic hepatitis and liver cirrhosis, but in these conditions, IL-6 is expressed mainly by myeloid cells/leukocytes rather than parenchymal cells (Deviere et al., 1989; Kakumu et al., 1993; Soresi et al., 2006) . Our studies indicate that the critical site of IL-6 expression shifts from myeloid cells to epithelial cells during the course of DEN-induced liver tumorigenesis. Initially, DEN administration rapidly induces IL-6 in Kupffer cells through NF-kB activation (Maeda et al., 2005) . This initial surge in IL-6 is required for DEN-induced hepatocarcinogenesis (Naugler et al., 2007) . Although IL-6 decays within 2 weeks of DEN administration, it reappears several months later, but at that time, it is expressed within FAH. IL-6 expression is also elevated in isolated HcPCs and is maintained in fully transformed HCC cells. Furthermore, autocrine IL-6 is important for HcPC to HCC progression and for tumorigenic growth. Autocrine IL-6 in both HcPC and HCC cells depends on elevated expression of LIN28, an RNA-binding protein that exerts its protumorigenic activity through downregulation of Let-7, an miRNA that inhibits IL-6 expression (Viswanathan and Daley, 2010) . Accordingly, HcPCs exhibit downregulation of both Let-7f and Let-7g, and elevated LIN28 is found not only in isolated HcPCs but also within FAH and human HCV-induced dysplastic lesions.
A similar LIN28-Let-7-IL-6 epigenetic switch is important for in vitro programming and maintenance of cancer stem cells (Iliopoulos et al., 2009 ). IL-6 also induces malignant features in human ductal carcinoma stem cells (Sansone et al., 2007) . In fact, autocrine IL-6 signaling was suggested to play a key role in STAT3-dependent tumor progression (Grivennikov and Karin, 2008) . Another miRNA-driven autoregulatory circuit involved in hepatocarcinogenesis accounts for elevated IL-6R expression (Hatziapostolou et al., 2011 ). Yet, HcPC-containing aggregates also express several other STAT3-activiting cytokines and receptors. Accordingly, silencing or ablation of IL-6 results in incomplete inhibition of HcPC to HCC progression. Nonetheless, our results demonstrate that autoregulatory circuits/epigenetic switches play an important role in the very early stages of tumorigenesis. Given that such circuits are already activated in premalignant cells, pharmacological agents that disrupt their function may be useful in cancer prevention. Prevention is of particular importance in cancers such as HCC, which is often detected at a stage that is refractory to currently available therapeutics.
EXPERIMENTAL PROCEDURES
Mice, HCC Induction, HcPC Isolation, and Transplantation MUP-uPA transgenic mice (Weglarz et al., 2000) were maintained on a pure BL/6 background. Because homozygous females frequently die when pregnant, MUP-uPA heterozygotes were generated by backcrossing homozygous MUP-uPA males with BL/6 females to be used as recipients for hepatic transplantation. Tak1 Dhep (Inokuchi et al., 2010) and Il6 F/F (Quintana et al., 2013) mice were also in the BL/6 background. Il6 Dhep mice were generated by crossing Il6 F/F and Alb-Cre mice. C57BL/6 actin-GFP mice were from the Jackson Laboratories. BL/6 mice were purchased from Charles River Laboratories.
To induce HCC, 15-day-old mice were injected i.p. with 25 mg/kg DEN (Sigma). A pool of DEN-injected BL/6 mice was maintained and used in most experiments. Hepatocytes were isolated using a two-step procedure . Cell aggregates were isolated by filtration through 70 and 40 mm sieves. To disperse the aggregates into single cells, they were subjected to gentle pipetting in Ca/Mg-free PBS on ice. Single-cell suspensions of aggregated and nonaggregated hepatocytes were transplanted via an i.s. injection into 21-day-old male MUP-uPA mice . Alternatively, singlecell suspensions of aggregated hepatocytes were enriched for CD44 + HcPC using magnetic beads. As few as 100 viable CD44 + cells mixed with 1 3 10 5 normal hepatocytes from normal males were transplanted into MUP-uPA mice. Alternatively, BL/6 mice were pretreated with retrorsine (70 mg/kg i.p.) (Sigma), a cell-cycle inhibitor, 1 month prior to transplantation. Transplanted mice were allowed to recover for 1 week and then injected weekly with 33 0.5 ml/kg CCl 4 i.p. to induce liver injury and hepatocyte proliferation (Guo et al., 2002) . Mice were sacrificed 5 to 6 months later, and tumors bigger than 1 mm in diameter on the liver surface were counted. Tumors bigger than 5 mm across were dissected for biochemical and molecular analyses.
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